Goldman Sachs
NVCR icon

Goldman Sachs’s NovoCure NVCR Stock Holding History

Goldman Sachs’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.13M Sell
745,435
-432,610
-37% -$5.4M ﹤0.01% 3238
2025
Q4 		$15.2M Buy
1,178,045
+273,539
+30% +$3.51M ﹤0.01% 2646
2025
Q3 		$11.7M Buy
904,506
+153,990
+21% +$2.06M ﹤0.01% 2812
2025
Q2 		$13.4M Sell
750,516
-243,154
-24% -$4.24M ﹤0.01% 2492
2025
Q1 		$17.7M Buy
993,670
+52,180
+6% +$1.19M ﹤0.01% 2141
2024
Q4 		$28.1M Buy
941,490
+155,745
+20% +$3.3M ﹤0.01% 1802
2024
Q3 		$12.3M Buy
785,745
+544,232
+225% +$9.87M ﹤0.01% 2517
2024
Q2 		$4.14M Sell
241,513
-88,391
-27% -$1.55M ﹤0.01% 3339
2024
Q1 		$5.16M Buy
329,904
+8,982
+3% +$132K ﹤0.01% 3060
2023
Q4 		$4.79M Buy
320,922
+195,079
+155% +$2.61M ﹤0.01% 3194
2023
Q3 		$2.03M Buy
125,843
+13,175
+12% +$380K ﹤0.01% 3758
2023
Q2 		$4.68M Sell
112,668
-39,951
-26% -$2.48M ﹤0.01% 3159
2023
Q1 		$9.18M Sell
152,619
-120,014
-44% -$9.59M ﹤0.01% 2501
2022
Q4 		$20M Buy
272,633
+3,036
+1% +$228K ﹤0.01% 1964
2022
Q3 		$20.5M Buy
269,597
+18,626
+7% +$1.45M 0.01% 1846
2022
Q2 		$17.4M Buy
250,971
+47,517
+23% +$3.58M ﹤0.01% 2015
2022
Q1 		$16.9M Sell
203,454
-105,480
-34% -$7.77M ﹤0.01% 2189
2021
Q4 		$23.2M Buy
308,934
+82,446
+36% +$8.28M ﹤0.01% 1982
2021
Q3 		$26.3M Sell
226,488
-9,436
-4% -$1.43M 0.01% 1803
2021
Q2 		$52.3M Buy
235,924
+85,802
+57% +$16.7M 0.01% 1217
2021
Q1 		$19.8M Sell
150,122
-193,933
-56% -$30.7M 0.01% 1938
2020
Q4 		$59.5M Buy
344,055
+148,277
+76% +$20.3M 0.02% 985
2020
Q3 		$21.8M Sell
195,778
-177,256
-48% -$14.2M 0.01% 1680
2020
Q2 		$22.1M Sell
373,034
-36,724
-9% -$2.42M 0.01% 1601
2020
Q1 		$27.6M Sell
409,758
-4,566
-1% -$361K 0.01% 1275
2019
Q4 		$34.9M Sell
414,324
-158,010
-28% -$12.8M 0.01% 1416
2019
Q3 		$42.8M Buy
572,334
+264,593
+86% +$21.2M 0.01% 1199
2019
Q2 		$19.5M Sell
307,741
-68,987
-18% -$3.5M 0.01% 1874
2019
Q1 		$18.1M Buy
376,728
+231,820
+160% +$11.2M 0.01% 1959
2018
Q4 		$4.85M Sell
144,908
-67,982
-32% -$2.49M ﹤0.01% 2906
2018
Q3 		$11.2M Sell
212,890
-134,796
-39% -$5.37M ﹤0.01% 2372
2018
Q2 		$10.9M Buy
347,686
+294
+0.1% +$8.18K ﹤0.01% 2347
2018
Q1 		$7.57M Buy
347,392
+241,929
+229% +$5.2M ﹤0.01% 2579
2017
Q4 		$2.13M Sell
105,463
-4,781,989
-98% -$92.1M ﹤0.01% 3750
2017
Q3 		$97M Sell
4,887,452
-100,555
-2% -$1.98M 0.02% 825
2017
Q2 		$86.3M Buy
4,988,007
+4,913,755
+6,618% +$63.4M 0.02% 868
2017
Q1 		$601K Sell
74,252
-18,703
-20% -$135K ﹤0.01% 4842
2016
Q4 		$730K Buy
92,955
+77,491
+501% +$623K ﹤0.01% 4731
2016
Q3 		$132K Sell
15,464
-4,141
-21% -$37.8K ﹤0.01% 6084
2016
Q2 		$229K Buy
19,605
+15,472
+374% +$194K ﹤0.01% 5586
2016
Q1 		$60K Buy
4,133
+3,777
+1,061% +$54.2K ﹤0.01% 6339
2015
Q4 		$8K Buy
+356
New +$8.5K ﹤0.01% 7000

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Goldman Sachs's NVCR Position: Q1 2026 in Review

Goldman Sachs reduced its NovoCure (NVCR) stake by 37% in Q1 2026, selling an estimated $5.4M and leaving 745,435 shares worth $8.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

Goldman Sachs first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $97M in Q3 2017. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Goldman Sachs held 745,435 shares of NovoCure worth $8.13M as of Q1 2026.
  • Goldman Sachs sold 432,610 NovoCure shares in Q1 2026, an estimated $5.4M.
  • NovoCure made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3238 holding.
  • Goldman Sachs first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
  • Goldman Sachs's NovoCure position peaked at $97M in Q3 2017.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.